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Background: Previous studies showed that adjunctive subantimicrobial dose doxycycline (SDD; 20 mg,
twice daily) provides significant clinical benefits to scaling and root planing (SRP). A modified-release SDD
formulation containing 40 mg doxycycline (SDD-40) to be taken once daily has been developed. The aim of
this study was to investigate the efficacy of SDD-40 when used as an adjunct to SRP for the treatment of peri-
odontitis.
Methods: A 9-month, double-masked, randomized, placebo-controlled, multicenter study was con-
ducted to test the efficacy of adjunctive SDD-40 in 266 subjects with periodontitis. Subjects were treated
by SRP and randomized to receive SDD-40 or placebo for 9 months with evaluations at 3, 6, and 9 months.
Results: Adjunctive SDD-40 provided significantly greater clinical benefits than placebo at all time
points. At month 9, at sites with baseline probing depths (PD) ‡6 mm, 72% to 76% of sites in the SDD-40
group demonstrated clinically significant PD reductions and clinical attachment level (CAL) gains ‡2 mm
compared to 56% to 58% of sites in the placebo group (P <0.0001); 48% to 52% of sites in the SDD-40 group
demonstrated PD reductions and CAL gains ‡3 mm compared to 32% of sites in the placebo group
(P <0.0001). In moderate sites (baseline PD 4 to 6 mm), adjunctive SDD-40 provided significant clinical
benefits compared to placebo for mean CAL (all time points: P <0.05), PD (3 months: P = 0.002; 6 and 9
months: P = 0.001), and bleeding on probing (BOP) (3 months: P <0.01; 6 months: P <0.02; 9 months:
P <0.05). In deep sites (baseline PD ‡7 mm), SDD-40 provided significant benefits over control for mean
CAL (3 months: P <0.05; 6 and 9 months: P <0.01), PD (all time points: P <0.001), and BOP (3 months:
P <0.05; 6 months: not statistically significant; 9 months: P <0.05). Compliance with study medication
was high (>92%) with no significant differences in adverse events between groups and no evidence of mi-
crobiologically significant changes or development of antibiotic resistance in the subgingival flora in either
group.
Conclusion: SDD-40 used as an adjunct to SRP resulted in significantly greater clinical benefits than SRP
alone in the treatment of periodontitis. J Periodontol 2008;79:440-452.
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S
ubantimicrobial dose doxycycline‡‡ (SDD;
doxycycline, 20 mg, twice daily) has become
widely established as an effective adjunctive
systemic therapy in the management of periodontitis.
Clinical studies1-5 confirmed that when used as an
adjunct to scaling and root planing (SRP) for the
treatment of periodontal disease, SDD results in
statistically and clinically significant improvements
over those achieved by SRP alone. In addition, the
long-term use of SDD has been shown to be safe, and
it is not associated with the development of antibiotic
resistance in the periodontal microflora,6 the skin
microflora (when used long-term for the management
of inflammatory conditions, such as acne),7 or the
flora of the gastrointestinal or genitourinary tracts.8
The clinical benefits of SDD derive from the ability
of doxycycline to inhibit the activity of matrix metal-
loproteinases (MMPs).9 MMPs play a key role in peri-
odontal pathogenesis and are secreted by a variety
of resident and infiltrating inflammatory cells in dis-
eased periodontal tissues. MMP levels are increased
pathologically in inflamed periodontal tissues and in
gingival crevicular fluid (GCF) from deep periodontal
pockets.10 Administration of SDD was shown clearly
to result in statistically significant decreases in GCF-
derived MMPs and bone breakdown components; it
also promoted concomitant improvements in the clin-
ical measurements of periodontal status.4,11,12 SDD
was shown to improve clinical outcomes when used
as an adjunct to periodontal flap surgery and to reduce
GCF concentrations of markers of alveolar bone re-
sorption.13 SDD, by virtue of its anti-inflammatory
and anti-MMP effects, was also shown to be of poten-
tial benefit in the management of systemic conditions
such as coronary artery disease,14 rheumatoid arthri-
tis,15 and adult acne and rosacea.16
The decision whether to use a systemic adjunct to
conventional periodontal therapies must be made af-
ter consideration of many factors including the di-
agnosis, the desired treatment outcomes, and the
patient’s wishes following full explanation of all treat-
ment options. Clearly, the use of a systemic medica-
tion over 3 to 9 months requires a commitment on the
part of the patient, and poor compliance with a twice-
daily medication may affect clinical outcomes. In dis-
orders such as hypertension, it has been shown that
compliance with medication is increased as the fre-
quency of daily dosing is decreased.17,18 Thus, in
terms of compliance, once-daily dosing is preferred
to twice-daily (or more) dosing whenever possible.
Although reducing the frequency of dosing en-
hances compliance and usually is preferred by pa-
tients,19 this can create challenges in maintaining
circulating drug concentrations at the correct thera-
peutic level. These difficulties may be countered by
formulating modified-release systems in which the re-
lease and subsequent absorption of a medication is
prolonged, thereby ensuring the correct therapeutic
dose for an extended period of time. A modified-
release formulation of SDD has been developed
containing doxycycline monohydrate 40 mg in con-
trolled-release capsules§§ to be taken once daily
(SDD-40). Therefore, the objective of this study was
to evaluate the efficacy of SDD-40 when used as an
adjunct to SRP compared to placebo for the treatment
of periodontitis. Furthermore, the effect, if any, of a
9-month regimen of SDD-40 on the subgingival flora
was evaluated compared to the placebo control.
MATERIALS AND METHODS
Study Design
This was a randomized, multicenter, double-masked,
placebo-controlled parallel group study to evaluate
the efficacy of SDD-40 when used as an adjunct to
SRP in the treatment of periodontitis. The duration
of the study was ;9.5 months, consisting of a 2-week
screening process and a 9-month treatment period.
Subjects were assigned randomly to treatment with
SDD-40 or placebo once daily for 9 months. The study
was conducted between May 2004 and August 2005
at seven clinical investigational sites (Universities of
Kentucky, Texas at San Antonio, Florida, Pennsylva-
nia, Michigan, and Newcastle upon Tyne and a private
practice in San Francisco), with all microbiologic as-
says conducted at West Virginia University. Approval
was granted by the respective institutional review
boards or ethics committee of the study centers prior
to study initiation. Written informed consent was ob-
tained from all subjects. Subjects were screened to
confirm eligibility and then underwent full-mouth
SRP at the baseline visit. Following this, subjects were
allocated randomly to receive adjunctive SDD-40 or
adjunctive placebo for the treatment period of the
study (9 months) commencing at baseline. Subjects
returned to their respective study center for evalua-
tions at 3, 6, and 9 months after baseline.
Study Population
Eligible subjects were male or female, ‡18 years old,
with evidence of untreated periodontitis manifested
by four periodontal sites in each of two quadrants,
i.e., eight qualifying periodontal sites, with a minimum
of two affected teeth per quadrant, with all eight qual-
ifying sites demonstrating probing depth (PD) ‡5 mm,
attachment loss ‡5 mm, and bleeding on probing
(BOP) score20 ‡1, with at least two sites having bleed-
ing scores ‡2. Exclusion criteria included pregnant
or nursing females; serious medical conditions, e.g.,
kidney or liver disease; systemic infection; dental
prophylaxis within the last 30 days; requirement for
‡‡ Periostat, CollaGenex Pharmaceuticals, Newtown, PA.
§§ Oracea, CollaGenex Pharmaceuticals.
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antibiotic prophylaxis prior to dental procedures; use
of non-tetracycline antibiotics within 6 weeks of base-
line; use of tetracycline antibiotics within 3 months
of baseline; hypersensitivity to tetracyclines; a re-
quirement for chronic (‡2 weeks) antibiotic therapy;
surgery to bypass or exclude the duodenum; and
achlorhydria.
Procedures
Written informed consent was obtained at the screen-
ing examination. A health history was recorded, and
an oral pathology examination was undertaken. Full-
mouth clinical attachment level (CAL) and PD mea-
sures were recorded by trained examiners using
manual University of North Carolina 15 periodontal
probes at six sites per tooth. BOP was recorded at
six sites per tooth using a bleeding index (0 = no bleed-
ing; 1 = single bleeding point or fine line of blood; 2 =
interdental triangle or direct margin fills with blood;
and 3 = profuse bleeding immediately after prob-
ing).20 Venous blood samples were obtained, and a
pregnancy test was performed when appropriate to ex-
clude pregnancy. Radiographs taken within 12 months
of screening (including any taken at the screening ap-
pointment itself) were used to confirm the periodontal
diagnosis and identify any underlying conditions that
might exclude a subject from participation in the
study. Demographic information, details of oral hy-
giene practices, and smoking histories were recorded.
The screening examination also served as the
baseline examination for those subjects who immedi-
ately qualified for the study. Otherwise, subjects re-
turned for the baseline examination 14 days after
screening. In either case, following the baseline exam-
ination, full-mouth SRP was undertaken commencing
immediately after the baseline examination and com-
pleted within a maximum of 24 hours. SRP was per-
formed by supra- and subgingival use of ultrasonic
instruments followed by hand instruments for removal
of plaque and calculus deposits until tooth surfaces
were smooth and calculus could not be detected, with
a time limit of 1 hour per quadrant. Ultrasonic and uni-
versal or area-specific curets were used, as was local
anesthesia, based on operator preference.
At baseline, subjects were randomized to receive
SDD-40 or placebo once daily (1:1 randomization).
Randomization was carried out at each investigational
site based on a randomly generated predefined
schedule with fixed block size. Subjects were in-
structed to take study medication with water ‡1 hour
before or 2 hours after meals. Subjects were instructed
that antacids and nutritional supplements containing
Al, Ca, or Mg may impair drug absorption and that
these were to be taken ‡1.5 hours before or 3 hours
after taking study medication. Study medication
and placebo were identical in appearance and were
dispensed in 3-month quantities. All personnel in-
volved in the study were masked to study medication
allocation. Subjects returned for full-mouth clinical
assessments at 3, 6, and 9 months and were con-
tacted monthly by telephone for the recording of ad-
verse events (AEs) and for ensuring compliance. At
month 9, a dental prophylaxis was performed, and
the subjects were exited from the study.
Assessments
Prior to the study, all examiners were trained and
practiced in each of the clinical measurements. To
minimize the impact of interexaminer variability, the
same examiner assessed a given subject for the dura-
tion of the study. Prior to the primary statistical ana-
lyses, sites were stratified by the degree of PD at
baseline: sites with PD of 1 to 3 mm were considered
normal; sites with PD of 4 to 6 mm were considered
mild-moderately diseased; and sites with baseline
PD ‡7 mm were considered severely diseased.21
Full-mouth PD, BOP, and CAL were recorded at
baseline and months 3, 6, and 9. Efficacy parameters
included the mean changes in PD, BOP, and CAL
score from baseline. AEs and the use of concomitant
medications were documented in subject diaries and
recorded at each study visit and during monthly tele-
phone contacts. Compliance with study drug therapy
was recorded by counting the number of tablets dis-
pensed and returned. Laboratory tests (blood chemis-
try and complete blood cell count and differentiation)
were conducted at the screening/baseline visit and
month 9. Vital signs, oral soft tissue examinations,
and examinations of the head and neck were per-
formed at screening/baseline and at months 3, 6,
and 9. The pregnancy test was repeated at month 9
when appropriate.
Microbiologic Assessments
At two preselected investigational centers (University
of Kentucky and University of Florida), subgingival
plaque samples were collected using sterile paper
points at baseline and month 9 and analyzed for mi-
croflora and antibiotic susceptibility. Plaque was col-
lected from four of the eight selected qualifying sites
with PD ‡5 mm and £8 mm. Obvious supragingival
plaque was removed and discarded. Subgingival
samples were collected by inserting a single sterile
endodontic paper point into the pocket until resis-
tance was felt. The paper point was moved laterally
parallel to the long axis of the tooth and left in place
for ;10 seconds as described previously.6 The point
was removed and immediately placed in modified
Amies transport medium.22 A separate paper point
was used to sample each site, but the sites were
pooled by subject for processing.
For analysis (undertaken at West Virginia Uni-
versity), samples were dispersed by low wattage
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sonication and vortexing for 10 seconds using anaer-
obic techniques. Ten-fold serial dilutions were made
under anaerobic conditions using prereduced anaer-
obically sterilized (PRAS) Ringers solution, and 0.1-
ml aliquots were dispensed onto the surface of agar
plates and spread with sterile glass rods. Following
the prescribed incubation period, plates were exam-
ined for colony forming units (CFU). Counts for the
enumeration of total anaerobic and total facultative
counts were performed on the plate dilutions that gave
rise to 20 to 200 CFU. Counts on selective media were
performed using the plate dilutions that yielded 20 to
200 CFU.
To determine the effect of SDD-40 on the total cul-
tivable flora, 0.1-ml aliquots of the diluted samples
were spread onto trypticase-soy blood agar supple-
mented with hemin and menadione (TSBA-HK) me-
dium containing 4 mg doxycycline per milliliter of
medium (TSBA + doxycycline). These plates were in-
cubated anaerobically along with the TSBA-HK plates
for the determination of total anaerobic bacterial
counts. Following 5 to 7 days of incubation, both sets
of plates (TSBA-HK doxycycline containing and non-
doxycycline containing) were examined for CFU. The
colonies on the countable TSBA + doxycycline plates
were examined; colonies belonging to each of the
most numerous colony types present (up to three dif-
ferent colony types per sample when present) were
counted, and a representative isolate of each was sub-
cultured to TSBA-HK. Each isolate that survived sub-
culture was identified to genus and species level. The
minimal inhibitory concentrations (MICs) of doxycy-
cline, minocycline, tetracycline, erythromycin, clin-
damycin, and amoxicillin were determined by agar
dilution or by the E-test for each isolate that survived
the characterization and identification process.6,23
This procedure yielded the following: percentage of
the cultivable flora resistant to doxycycline, the iden-
tity of the predominant doxycycline-resistant flora,
and the presence or absence of multiantibiotic re-
sistance and the particular antibiotics to which the
microorganism was resistant. The percentage of cul-
tivable flora resistant to doxycycline was calculated
from the total counts on doxycycline-containing me-
dium as a percentage of the total anaerobic counts on
non-doxycycline–containing medium.
Statistical Analyses
The study was designed to detect a difference ‡0.2
mm in mean change from baseline CAL between
treatment arms (two-tailed tests) with 80% power, as-
suming that 72 subjects would complete the study in
each group. An intent-to-treat analysis strategy was
used for all subjects who were randomized to study
medication and who took at least one dose. For sub-
jects not completing the study, a last-observation-
carried-forward (LOCF) algorithm was used to impute
missing data at each time point.
Changes in mean CAL, PD, and BOP were calcu-
lated at each time point from subject means catego-
rized according to PD at baseline. Comparisons
between the treatment groups were made using anal-
ysis of covariance (ANCOVA). The ANCOVA model
analyzed the subject-level mean changes from base-
line; included factors for treatment group, investiga-
tional site, and the treatment by investigational site
interaction; and included the baseline value of the pa-
rameter for each subject as covariate. All tests of sig-
nificance were two-sided; differences were considered
statistically significant when P <0.05.
For sites requiring additional periodontal therapy
during the course of the study (those sites that dem-
onstrated ‡2 mm attachment loss at any point during
the study), the post-baseline observations recorded
immediately prior to the local therapy were analyzed
using the LOCF strategy to ensure analyses were con-
servative and not biased. Differences between the
groups for threshold changes indicating disease pro-
gression, i.e., ‡2 mm attachment loss, were analyzed
using a generalized estimating equations (GEE) anal-
ysis for the repeated measures across visits.
To assess the clinical significance of any improve-
ments in periodontal status as a result of treatment,
the number of sites achieving clinically significant re-
ductions in PD, i.e., reductions ‡2 and ‡3 mm, and
clinically significant gains in CAL, i.e., gains ‡2 and
‡3 mm, were determined. Separate analyses were
done for all sites with baseline PD ‡4 mm and for
deeper sites with baseline PD ‡6 mm. The proportion
of sites achieving such improvements in each group
was expressed as a percentage of the total number
of sites, and comparisons between the two treatment
groups were made using a GEE model with adjust-
ment for within-subject correlations among sites.
Compliance with study medication was defined as
the number of medication doses taken as a percent-
age of the number that should have been taken based
on the number of days between study visits. Non-
compliance was defined if compliance was £80%.
The microbial data from both clinical centers that
collected plaque samples were combined and ana-
lyzed as a single data set. Inferential analyses of doxy-
cycline resistance were based on the per-subject
mean percentage of colonies at each visit that showed
resistance to doxycycline and the change from base-
line in the mean percentage of resistant organisms. In-
ferential analyses of species-specific colony counts
were based on log (10)-transformed counts, where
the log (10) transformation of a count of zero was
set to zero. The primary analyses sought to determine
whether there were statistically significant differences
between active and placebo groups in changes from
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baseline to month 9 with regard to the mean percent-
age of doxycycline-resistant organisms. Separate
analyses were conducted for each of the visits and
for the changes from baseline to month 9 using the
Wilcoxon two-sample test. This non-parametric test
was chosen because distributions of the per-subject
percentage of resistance data did not meet the re-
quirements for parametric analyses. It is a conserva-
tive test that provides unbiased probability estimates
under these circumstances. The secondary analyses
were performed to determine whether colony counts
for specific species were different between the two
treatment groups at either visit and whether the
changes from baseline in mean log (10) counts dif-
fered between treatment groups. As in the case of
the primary analyses, separate analyses were con-
ducted for each of the visits and for the changes from
baseline using the Wilcoxon two-sample test. In all
cases, two-tailed P values £0.05 were considered
statistically significant. All analyses were performed
using a software program.ii
RESULTS
A total of 266 subjects were enrolled into the study;
133 were randomized to receive adjunctive SDD-40,
and 133 were randomized to receive adjunctive pla-
cebo. A total of 110 subjects (82.7%) in the SDD-40
group and 117 subjects (88.0%) in the placebo group
completed the study. The primary reasons for discon-
tinuing participation were loss to follow-up (SDD-40
group: 10 subjects; placebo group: four subjects),
AEs (SDD-40 group: seven subjects; placebo group:
four subjects) or lack of compliance (SDD-40 group:
two subjects; placebo group: four subjects). There
were no statistically significant differences between
the SDD-40 and placebo groups with respect to the
numbers of subjects who did not continue the study
or the reasons for discontinuation.
There were no statistically significant differences
between the treatment groups regarding demo-
graphic characteristics (Table 1). Similarly, there
were no significant differences between the study
groups with respect to oral hygiene practices. On av-
erage, subjects brushed their teeth twice per day and
flossed just over three times per week. Eighteen of 266
(6.8%) subjects had diabetes; one subject had type
1 diabetes mellitus (this subject was randomized to re-
ceive placebo), and 17 had type 2 diabetes mellitus
(nine subjects in the SDD-40 group and eight subjects
in the placebo group). There were no statistically sig-
nificant differences in diabetes status between the
treatment groups (P = 0.59). The treatment groups
also were similar with regard to other baseline vari-
ables, including medical history, medication history,
and use of concomitant medications. Compliance
with the study medications was high, with 92% com-
pliance in the SDD-40 group and 95% compliance
in the placebo group.
Baseline clinical parameters are shown in Table 2.
There were no statistically significant differences in
the baseline clinical characteristics between the two
treatment groups.
Clinical Outcomes
The mean per-subject changes in CAL from baseline
to month 9 are shown in Figures 1 and 2. Attachment
gains were demonstrated in both groups, which was
expected following SRP. However, gains in CAL were
significantly greater at all time points in the subjects
treated with SDD-40 compared to the subjects who re-








(n = 133) P
Age (years)
Mean – SD 48.5 – 11.4 49.9 – 11.0 0.34
Range 24 to 81 23 to 82
Gender (n [%])
Male 58 (43.6) 62 (46.6) 0.62
Female 75 (56.4) 71 (53.4)
Race/ethnicity (n [%])
White 87 (65.4) 100 (75.2) 0.90
Black 28 (21.1) 21 (15.8)
Asian 8 (6.0) 7 (5.3)
Other 10 (7.5) 5 (3.7)
Tobacco use (n [%])
Ex- or current smoker 82 (62.6) 84 (62.2) 0.95
Current smoker 45 (34.4) 32 (23.7) 0.06
P values were determined using the x2 test for discrete variables and the
two-sample t test for continuous variables.
Table 2.
Baseline Clinical Characteristics
(mean – SEM) of Study Population
Baseline PD Parameter SRP + SDD-40 SRP + Placebo P
4 to 6 mm PD (mm) 4.91 – 0.02 4.89 – 0.02 0.46
CAL (mm) 4.81 – 0.09 4.82 – 0.09 0.78
BOP 1.89 – 0.04 1.88 – 0.04 0.81
‡7 mm PD (mm) 7.43 – 0.06 7.47 – 0.06 0.62
CAL (mm) 7.18 – 0.16 7.30 – 0.15 0.60
BOP 2.14 – 0.04 2.10 – 0.05 0.51
ii SAS version 8.2, SAS Institute, Cary, NC.
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(baseline PD 4 to 6 mm) or deep (baseline PD ‡7 mm)
sites. In moderate sites at month 9, mean CAL gains
from baseline were 11% greater with adjunctive SDD-
40 than with placebo (1.66 mm versus 1.49 mm, re-
spectively; P = 0.02). In deep sites at month 9, mean
CAL gains from baseline were 19% greater with ad-
junctive SDD-40 than with placebo (2.62 mm versus
2.20 mm, respectively; P <0.01).
The mean per-subject changes in PD from baseline
to month 9 are shown in Figures 3 and 4. Again, as was
expected following SRP, PD reductions were observed
in both groups. These were significantly greater at all
time points, at moderate and deep sites, in the sub-
jects treated with SDD-40 compared to the subjects
who received placebo (P <0.01). In moderate sites
at month 9, mean PD reductions from baseline were
16% greaterwithadjunctive SDD-40 than withplacebo
(1.63 mm versus 1.41 mm, respectively; P <0.01). In
deep sites at month 9, mean PD reductions from base-
line were 22% greater with adjunctive SDD-40 than
with placebo (2.74 mm versus 2.25 mm, respectively;
P <0.001).
Although mean changes in PD and CAL are useful
summary statistics, they do not lend themselves eas-
ily to interpretation of whether improvements are clin-
ically significant. Therefore, a threshold analysis was
undertaken to determine the proportion of sites un-
dergoing PD reductions and CAL gains ‡2 and ‡3 mm
in the two treatment groups. Table 3 presents the
results of this analysis and confirms that, in every
Figure 1.
Mean attachment gains in sites with baseline PD of 4 to 6 mm. The
mean per-subject changes from baseline and standard errors are
presented. *P <0.05 versus placebo.
Figure 2.
Mean attachment gains in sites with baseline PD ‡7 mm. The mean
per-subject changes from baseline and standard errors are presented.
*P <0.05 versus placebo; †P <0.01 versus placebo.
Figure 3.
Mean PD reductions in sites with baseline PD of 4 to 6 mm. The mean
per-subject changes from baseline and standard errors are presented.
†P <0.01 versus placebo.
Figure 4.
Mean PD reductions in sites with baseline PD ‡7 mm. The mean
per-subject changes from baseline and standard errors are presented.
‡P <0.001 versus placebo.
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instance, a substantial and
highly statistically significant
benefit of SDD-40 was ap-
parent. For example, when
considering the most dis-
eased sites (baseline PD ‡6
mm), ;48% to 52% of sites
in the SDD-40 group dem-
onstrated highly clinically
significant PD reductions
and CAL gains ‡3 mm com-
pared to ;32% of sites in the
placebo group (P <0.0001).
Similarly, ;72% to 76% of
sites with baseline PD ‡6
mm in the SDD-40 group
demonstrated clinically sig-
nificant PD reductions and
CAL gains ‡2 mm compared
to 56% to 58% of sites in the
placebo group (P <0.0001).
Mean changes in BOP
scores are presented in Ta-
ble 4. Reductions in mean
BOP scores were observed
in both treatment groups fol-
lowing SRP, as was expected.
However, reductions in BOP
were significantly greater in
the SDD-40 group than the placebo group at all time
points in moderate and deep sites (with the exception
of deep sites at month 6, at which there was no signif-
icant difference between SDD-40 and placebo).
The percentage of sites demonstrating progressing
disease manifested by attachment loss ‡2 or ‡3 mm
from baseline are presented in Table 5. There was a
tendency for subjects in the SDD-40 group to demon-
strate a slightly lower percentage of sites with attach-
ment loss ‡2 and ‡3 mm from baseline compared to
the placebo group, but these differences were not
statistically significant.
Safety Data
In the SDD-40 group, 88 subjects (66.2%) reported a
total of 217 AEs; 94 subjects (70.7%) reported a total
of 229 AEs in the placebo group. In the SDD-40
group, the most frequently reported AEs were
Table 3.
Threshold Analyses of Sites Demonstrating Clinically Significant CAL Gains and PD
Reductions at Month 9
Threshold Change
From Baseline
All Sites (baseline PD ‡4 mm) Deep Sites (baseline PD ‡6 mm)
SRP + SDD-40
(n = 8,260) (% [n])
SRP + Placebo
(n = 8,046) (% [n])
SRP + SDD-40
(n = 2,748) (% [n])
SRP + Placebo
(n = 2,630) (% [n])
CAL gain ‡2 mm 57.3* (4,732) 45.8 (3,688) 71.8† (1,973) 55.9 (1,469)
CAL gain ‡3 mm 28.3* (2,337) 19.5 (1,569) 47.3† (1,299) 31.6 (831)
PD reduction ‡2 mm 57.7* (4,769) 45.1 (3,626) 75.9† (2,086) 57.8 (1,520)
PD reduction ‡3 mm 25.4* (2,069) 16.5 (1,324) 51.7† (1,420) 32.1 (845)
* P <0.01 compared to placebo (determined using GEE model with adjustment for within-subject correlations among sites).
† P <0.0001 compared to placebo (determined using GEE model with adjustment for within-subject correlations among sites).
Table 4.
Changes (mean – SEM) in BOP From Baseline
SRP + SDD-40 SRP + Placebo SRP + SDD-40 SRP + Placebo
Month Moderate Sites (PD 4 to 6 mm) Deep Sites (PD ‡7 mm)
3 -1.19 – 0.13* -1.07 – 0.13 -1.20 – 0.16† -1.03 – 0.16
6 -1.26 – 0.13† -1.16 – 0.13 -1.31 – 0.13 -1.16 – 0.13
9 -1.27 – 0.12† -1.19 – 0.12 -1.31 – 0.14† -1.15 – 0.14
* P <0.01 compared to placebo.
† P <0.05 compared to placebo.
Negative numbers indicate reduction in BOP.
Table 5.
Per-Subject Percentage (mean – SEM) of Sites Demonstrating
Attachment Loss ‡2 and ‡3 mm From Baseline
SRP + SDD-40 SRP + Placebo SRP + SDD-40 SRP + Placebo
Attachment Loss Month Moderate Sites (PD 4 to 6 mm) Deep Sites (PD ‡7 mm)
‡2 mm 3 1.2 – 0.5 1.4 – 0.5 0.8 – 0.5 1.9 – 0.5
6 1.2 – 0.5 1.5 – 0.5 0.9 – 0.6 1.9 – 0.6
9 1.4 – 0.6 1.7 – 0.5 2.1 – 0.9 2.1 – 0.9
‡3 mm 3 0.3 – 0.2 0.4 – 0.2 0.4 – 0.3 0.9 – 0.3
6 0.3 – 0.2 0.6 – 0.2 0.5 – 0.4 1.0 – 0.4
9 0.6 – 0.3 0.9 – 0.3 0.3 – 0.4 1.2 – 0.4
Modified-Release SDD (SDD-40) Enhances SRP Volume 79 • Number 3
446
headache (13 subjects; 9.8%) and influenza and naso-
pharyngitis (each seven subjects; 5.3%). In the pla-
cebo group, the most frequently reported AEs were
sensitivity of teeth (13 subjects; 9.8%) and headache
and nasopharyngitis (each 10 subjects; 7.5%). AEs
were ranked as mild, moderate, or severe in intensity,
with the most common being mild or moderate. Se-
vere AEs were recorded for nine (6.8%) subjects in
the SDD-40 group and 18 (13.5%) subjects in the pla-
cebo group. No AE was considered to be probably re-
lated to the study medication in either group. Serious
AEs (SAEs) were reported for six (4.5%) subjects in
the SDD-40 group and three (2.3%) subjects in the
placebo group, and no SAE was considered to be re-
lated to treatment. Adjunctive SDD-40 was tolerated
well, and there were no clinically meaningful differ-
ences in the numbers of AEs between the treatment
groups, including any associated with the gastrointes-
tinal tract or genitourinary tract.
No clinically meaningful differences between the
placebo and SDD groups were found for any labora-
tory tests (complete blood cell count and blood chem-
istry), and there were no notable mean changes from
baseline to month 9 in either treatment group for any
laboratory parameter. No positive pregnancy tests were
recorded, and there were no differences between the
treatment groups in changes in vital signs or weight.
Microbiologic Outcomes
Data from 70 subjects (34 in the SDD-40 group and
36 in the placebo group) were available for microbio-
logic analysis. It was immediately apparent that an
imbalance existed between the two treatment groups
in the percentage resistance to doxycycline at the
baseline visit, and subjects randomized to SDD-40
presented with a three-fold greater load of doxycy-
cline-resistant bacteria (12.69%) than did subjects
randomized to placebo (3.95%) (Table 6). A similar
imbalance also was present at month 9 when twice
as many subjects in the SDD-40 group demonstrated
resistance to doxycycline compared to the placebo
group.However, whenconsidering the change indoxy-
cycline-resistant counts over the course of the study,
the two groups were very similar, with an increase of
just >5% in each treatment group. There were no sta-
tistically significant differences by parametric or non-
parametric analysis over time (P = 0.965, analysis of
variance; P = 0.156, Wilcoxon).
The effect of treatment, i.e., SDD-40 versus pla-
cebo, on the specific microbial taxa also was enumer-
ated. The microbial counts were log transformed (log
base 10) and then analyzed for differences at baseline
(imbalances) and at 9 months; because of the pres-
ence of an imbalance between treatment groups at
baseline, the change from baseline to 9 months also
was analyzed. These data are summarized in Table
7. Statistical analysis of the microbial counts in the
two treatment groups revealed that there were no sig-
nificant differences between the treatment groups
at baseline, month 9, or for the change over time
(Wilcoxon two-sample test). There were isolated sta-
tistically significant differences between the groups,
including a statistically significant difference between
treatment groups at baseline for Tannerella forsythia
(previously T. forsythensis) (P = 0.028) but not at
month 9 (P = 0.647). Statistically significant differ-
ences were detected for Porphyromonas gingivalis
(Pg) at month 9 (P = 0.043) and when change over
time was examined (P = 0.025). These differences
were due to the detection of Pg in a single subject
(700 CFU) at baseline in the SDD-40 group and in a
single subject (50,000 CFU) in the placebo group at
month 9.
The only other incidence of statistical significance
occurred with Aggregatibacter actinomycetemcomi-
tans (Aa) (previously Actinobacillus actinomycetem-
comitans). No differences were detected at baseline
between the two treatment groups (P = 0.356), but a
trend toward statistical significance was detected at
month 9 (P = 0.077), and significance was detected
in the change over time analysis (P = 0.002). In the
SDD-40 group, Aa was recovered in eight subjects
at baseline and nine subjects at month 9. In the pla-
cebo group, the respective numbers were 14 subjects
and eight subjects. Thus, the significance in change
over time was due to a decrease in Aa in the placebo
group and not due to an increase in the SDD-40 group.
To evaluate whether treatment with SDD-40 or pla-
cebo resulted in development of doxycycline or anti-
biotic resistance, bacteria that were recovered on
medium containing 4 mg/ml doxycycline were subcul-
tured, identified to genus and species by accepted mi-
crobiology methods, and then the MICs of the isolates
were determined for doxycycline, minocycline, tetra-
cycline, erythromycin, clindamycin, and amoxicillin.
MIC data are not readily analyzable by statistical
methods because each antibiotic concentration tested
represents a two-fold increase. Thus, MIC differences
Table 6.
Percentage (mean – SD) of Recovered
Flora Resistant to Doxycycline (4 mg/ml)
for Each Treatment Group
SDD-40 Placebo
Baseline 12.69 – 23.16 3.95 – 7.39
Month 9 17.79 – 20.85 9.33 – 20.64
Change from baseline
to month 9
5.09 – 31.17 5.38 – 22.02
J Periodontol • March 2008 Preshaw, Novak, Mellonig, et al.
447
of a single two-fold dilution are not considered mi-
crobially significant but would yield statistical sig-
nificance by parametric or non-parametric testing.
Such data are handled best by considering overall
changes in the bacterial profiles that show resistance
and by examining correlation coefficients to deter-
mine whether resistance to one agent promotes resis-
tance to a different agent.
Thus, a correlation matrix (Table 8) was created
based on the MICs obtained for the doxycycline-resis-
tant bacteria and their susceptibilities to doxycycline
and five other antibiotics. Because an imbalance was
found in the percentage resistance to doxycycline at
baseline for the two treatment groups, attention
should be directed at the comparison of correlation
coefficients within treatments rather than between
treatments. The only instance in which there was a mi-
crobiologically significant change was with amoxicil-
lin in the placebo group: a coefficient of 0.0927 was
obtained for the baseline data, and a coefficient of
0.3738 was obtained at 9 months. There were no
strong coefficients of correlation (>0.5) obtained be-
tween doxycycline resistance and resistance to any
of the other five antibiotics in the SDD-40 treatment
group.
Finally, Figure 5 provides a graphic representation
of the major taxonomic groups recovered and the pro-
portion that each contributed to the total doxycycline-
resistant profile. Although biologic system variation
is seen, there were no microbiologically significant
changes in the profiles obtained over time for the
SDD-40 group or the placebo group.
Table 7.
Means (log10) of Microbial Counts at Baseline and 9 Months by Treatment Group and
Change From Baseline to 9 Months
Bacterial Taxa
SDD-40 Placebo
Baseline Month 9 Change Over Time Baseline Month 9 Change Over Time
Total counts 4.5795 5.0584 0.4789 5.2814 5.5469 0.2655
P. gingivalis 0.0749 0 -0.0749 0 0.5119 0.5112
P. intermedia 0.8726 0.8240 -0.0486 1.1396 1.2110 0.0714
T. forsythia 0.5358 0.5972 0.0615 0.0644 0.5555 0.4911
A. actinomycetemcomitans 0.8335 1.3819 0.5484 1.2627 0.6092 -0.6536
E. corrodens 1.9259 1.9089 -0.0169 2.1573 2.1634 0.0061
F. nucleatum 1.4979 1.8691 0.3702 1.1517 1.4478 0.2961
Candida 0.6904 0.7175 0.0270 0.5410 0.2394 -0.3016
Enterics 0.6378 0.8912 0.2534 0.6828 0.3961 -0.2887
S. aureus 0.0847 0.1821 0.0974 0.1234 0.1974 0.0740
P. intermedia = Prevotella intermedia; E. corrodens = Eikenella corrodens; F. nucleatum = Fusobacterium nucleatum; S. aureus = Staphylococcus aureus.
0 = none detected; negative value = decrease over time.
Table 8.
Correlation Coefficients for Correlation of Resistance to Antibiotics With Resistance to
Doxycycline for Each Treatment and Sample Period
Amoxicillin Erythromycin Clindamycin Minocycline Tetracycline
SDD-40: baseline 0.4225 0.1652 0.2294 0.3778 0.2559
SDD-40: month 9 0.4945 0.2315 0.2660 0.1593 0.1208
Placebo: baseline 0.0927 0.2761 0.4373 0.6487 0.4322
Placebo: month 9 0.3738 0.2451 0.4480 0.6158 0.5137
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DISCUSSION
Previous investigations established the use of SDD
(20 mg, twice a day) as an adjunct to non-surgical
periodontal therapy. Improved treatment outcomes
were reported in clinical studies of subjects with
chronic periodontitis1,2,5 or severe, generalized
chronic periodontitis3 and in at-risk groups, such as
smokers24 and the institutionalized elderly.25 Reduc-
tions in GCF MMP levels were reported to coincide
with improvements in clinical status following SDD
treatment,4,11,12 and a benefit of SDD was reported
when used as an adjunct to periodontal flap surgery.13
SDD is remarkably well tolerated, with no evidence of
development of antibiotic resistance or any detrimen-
tal antimicrobial effects and no evidence of an adverse
safety profile.1,5,6,8 Thus, SDD is a valid and effective
adjunct in the treatment of periodontal disease and
should be one of the options for patients to consider
when deciding their treatment strategy in collabora-
tion with their clinician. Although compliance rates
were reported to be high (>87%) in a clinical trial5 of
the 20-mg formulation¶¶ of SDD taken twice daily, it
is well known in the medical community that compli-
ance and patient preference are increased if the fre-
quency of daily dosing is decreased.17-19 Therefore,
a once-daily 40-mg modified-release formulation of
SDD (SDD-40) as an adjunct for the treatment of peri-
odontitis was developed to improve patient compli-
ance while maintaining a consistent therapeutic
benefit.
The once-daily 40-mg dose (SDD-40) was com-
pared to placebo in this 9-month, randomized clinical
trial. A total of 266 sub-
jects with periodontitis





was very high (>92%
in total); therefore,






was tolerated very well
by the subjects, with no
AEs that were consid-
ered by the investigators
to be probably related to
study medication and
no SAEs that were con-
sidered related to study
treatments. There were
no significant differences in the numbers or types of
AEs between treatment groups, including those asso-
ciated with the gastrointestinal tract or skin (particu-
larly rash, photosensitivity reactions, and sunburn).
Surveillance for these latter categories of possible
AEs was particularly high, given the known pharma-
cology of doxycycline at antibiotic doses ‡100 mg.
As indicated in Table 1, the mean age of subjects
recruited to the study was ;48 to 50 years; although
the inclusion criteria allowed for subjects ‡18 years to
be recruited, the vast majority of those enrolled would
be assigned a diagnosis of chronic periodontitis using
the current classification system.26 Subjects were re-
cruited to the study based on the extent and severity of
periodontitis, as specified in the inclusion criteria.
Similar to previous studies of twice-daily 20-mg
formulations of SDD,1-3,5 improvements in mean
CAL and PD were significantly greater in the adjunc-
tive SDD-40 group than in the placebo group at every
follow-up examination (P <0.05). Consistent with ob-
servations that the magnitude of PD reductions and
CAL gains following SRP is related to the pretreatment
PD,21 in our study, the improvements in mean PD and
CAL were greater in sites with pretreatment PD ‡7 mm
compared to those with pretreatment PD of 4 to 6 mm.
In the deepest sites, at 9 months, mean CAL gains
were 19% greater and mean PD reductions were
22% greater with adjunctive SDD-40 compared to ad-
junctive placebo, representing a tangible clinical ben-
efit for subjects. It was reported that following SRP
Figure 5.
Profiles of bacterial taxa recovered at each sample period of each treatment that demonstrated resistance to
4 mg/ml doxycycline. Gm+ = Gram positive; Gm- = Gram negative; C. clostridioforme = Clostridium
clostridioforme; B. coagulans = Bacillus coagulans.
¶¶ Periostat, CollaGenex Pharmaceuticals.
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alone in deep sites (PD ‡7 mm), mean PD reductions
;2.16 mm and attachment gains ;1.19 mm can be
expected,21,27 whereas in our study, in subjects treated
with SRP and SDD-40, substantially greater clinical
improvements were identified in mean PD reductions
(2.74 mm at month 9) and mean CAL gains (2.62 mm
at month 9). In moderate sites (PD 4 to 6 mm), mean
PD reductions ;1.29 mm and mean CAL gains ;0.55
mm can be expected following SRP alone,21,27
whereas we identified mean CAL gains of 1.66 mm
and mean PD reductions of 1.63 mm in the subjects
treated with SRP and adjunctive SDD-40.
Compelling evidence to support the clinical benefit
of using SDD-40 as an adjunct to SRP is presented in
Table 3. Threshold analyses were undertaken to de-
termine the proportion of sites in each group that
demonstrated PD reductions and CAL gains ‡2 and
‡3 mm. These thresholds were chosen because they
represent a tangible clinical benefit that can be iden-
tified easily by a clinician with a periodontal probe. Al-
though changes in full-mouth mean PD and CAL
measurements are useful summary statistics for re-
search purposes, as clinicians, we never quantify a
subject’s treatment response in this way. Instead,
we assess clinically meaningful changes in periodon-
tal status, such as probing reductions above a certain
threshold, e.g., 2 mm. Therefore, the threshold ana-
lyses in this study were undertaken to assess the clin-
ical significance of any benefits of SDD-40. Table 3
provides abundantly clear evidence of the huge clin-
ical benefit of SDD-40 in this population. The benefit
of SDD-40 is particularly apparent when considering
deep sites that had PD ‡6 mm at the start of the study,
with ;72% to 76% of sites achieving PD reductions
and CAL gains ‡2 mm in the SDD-40 group compared
to 56% to 58% of sites achieving these improvements
in the placebo group. When considering an even more
stringent threshold of improvement of ‡3 mm, ;48%
to 52% of sites in the SDD-40 group achieved PD re-
ductions and CAL gains ‡3 mm compared to 32% of
sites in the placebo group. These impressive data un-
derscore the clinical benefit of adjunctive treatment
with SDD-40.
In this study, significantly greater reductions in
BOP were recorded in the SDD-40 group than in the
placebo group at all time points in the moderate sites
and at months 3 and 9 in the deep sites. Reductions in
BOP are consistent with improvements in periodontal
health; the absence of BOP is a good measure of
periodontal stability, indicating resolution of inflam-
mation, and is a predictor for the maintenance of peri-
odontal health.28 In this study, we interpreted the
significant reductions in BOP in the SDD-40 group
as indicative of enhanced clinical improvements
(manifested by greater PD reductions and CAL gains).
Previous studies1,5 of the 20-mg formulation of SDD
did not tend to identify significant differences between
treatment groups in BOP reductions, although this is
likely due to the different methodology used. Those
studies recorded BOP in a dichotomous fashion,
which may have lacked the discriminatory ability to
identify differences between groups compared to
the use of a graduated bleeding index as in the present
study.20
Consistent with previous studies,1,5 the number of
periodontal sites that demonstrated ongoing peri-
odontal breakdown (defined by loss of attachment
‡2 mm from baseline) was recorded, and appropriate
treatment was implemented following consultation
between the subject and the investigator. A small pro-
portion of sites demonstrated progressing disease
over the 9 months of the study (Table 5), and there
was a consistent benefit of SDD-40 in that fewer sites
with disease progression were identified. However,
because of the small number of sites, this failed to
achieve statistical significance.
From a microbiologic perspective, an objective of
this study was to determine whether SDD-40 exerted
any detectable effect on the subgingival flora associ-
ated with periodontally diseased sites. Pharmacoki-
netic studies demonstrated that once-daily SDD-40
yields steady-state serum levels ;0.5 to 0.6 mg/ml
(CollaGenex Pharmaceuticals, Newtown, Pennsylva-
nia; unpublished data), similar to the steady-state se-
rum levels of twice-daily 20-mg formulations of SDD
that were reported previously.29 This level is consider-
ably less than the MIC, determined in vitro using
planktonic-grown cultures, for the vast majority of
bacterial species isolated from the subgingival flora.
Antibiotic levels necessary to inhibit these same bac-
terial species grown in climax biofilms are 100- to
500-fold greater.30
However, the argument exists that sub-MIC levels
of an antibiotic may result in an increase in resistance
or the acquisition of resistance. To rule out this possi-
bility, a comprehensive microbial examination of the
subgingival flora was conducted immediately before
the first dosage and after 9 months of dosage with
SDD-40 or the placebo control. The effect of treat-
ment was determined by evaluating: 1) the increase
in resistance to doxycycline as an increase in the
MIC required to inhibit the bacteria and in the propor-
tion of the total bacteria recovered with resistance to
the drug; 2) increases or decreases in periodontal
and/or opportunistic pathogens; and 3) the develop-
ment of cross- and/or multiantibiotic resistance. An
imbalance existed at baseline between the two treat-
ment groups so that statistical testing was not pos-
sible between groups at either sampling time point.
However, when the data were analyzed for changes
between baseline and month 9, no statistical or micro-
biologically significant changes were detected in any
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of the parameters enumerated. The reason for the
imbalance between treatment groups at baseline is
not immediately clear. Variations between groups of
subjects may arise from biologic variation arising
purely by chance, sample methodology, or seasonal
changes. However, there is no evidence in this study
that any discernible factors could account for the dif-
ferences between the SDD-40 and placebo groups at
baseline, which we attribute purely to chance.
The results of the microbiologic analyses are in
agreement with previously published findings6-8,23,31
concerning 20-mg, twice-daily formulations of SDD.
They demonstrate that long-term use of SDD-40
does not result in a change in the microbial flora, an
increase in the proportion of the flora resistance to 4
mg/ml doxycycline, an increase or overgrowth by peri-
odontal or opportunistic pathogens, an increase in re-
sistance to doxycycline by any individual bacterial
species, the acquisition of doxycycline resistance by
bacteria previously susceptible, or the emergence of
cross-resistance or multiantibiotic resistance.
CONCLUSIONS
This study demonstrated that adjunctive SDD-40
taken for 9 months resulted in significantly greater
mean CAL gains and mean PD reductions compared
to those achieved by SRP alone during this time pe-
riod. More importantly, the clinical significance of
adjunctive SDD-40 was confirmed by threshold anal-
yses of the proportions of sites in each group achiev-
ing clinically relevant PD reductions and CAL gains ‡2
and ‡3 mm. These data are consistent with previous
studies1,5 that showed a clinical superiority when
twice-daily 20-mg formulations of SDD were used
as an adjunct to SRP. Also, similar to studies1,5 of
20-mg doses of SDD, SDD-40 was well tolerated,
and the number, type, and severity of AEs encoun-
tered were similar in the SDD-40 and placebo groups.
The data suggest that compliance was improved with
the once-daily formulation of SDD-40 compared to
previous studies of 20-mg doses, although this needs
to be confirmed in future studies. Again, similar to
studies6-8 of 20-mg doses of SDD, there was no evi-
dence of any long-term treatment effect of SDD-40
on the microbial flora, including any development of
antibiotic resistance. The data from this study confirm
that SDD-40 is a safe and effective therapy and sup-
port its use as an adjunct to SRP in the management of
subjects with periodontitis.
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